TWI759270B - 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法 - Google Patents

藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法 Download PDF

Info

Publication number
TWI759270B
TWI759270B TW105129257A TW105129257A TWI759270B TW I759270 B TWI759270 B TW I759270B TW 105129257 A TW105129257 A TW 105129257A TW 105129257 A TW105129257 A TW 105129257A TW I759270 B TWI759270 B TW I759270B
Authority
TW
Taiwan
Prior art keywords
cells
allogeneic
population
allogeneic cells
human patient
Prior art date
Application number
TW105129257A
Other languages
English (en)
Chinese (zh)
Other versions
TW201714619A (zh
Inventor
古恩德 寇恩
Original Assignee
美國紀念斯隆 凱特琳癌症中心
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美國紀念斯隆 凱特琳癌症中心 filed Critical 美國紀念斯隆 凱特琳癌症中心
Publication of TW201714619A publication Critical patent/TW201714619A/zh
Application granted granted Critical
Publication of TWI759270B publication Critical patent/TWI759270B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4242—Transcription factors, e.g. SOX or c-MYC
    • A61K40/4243—Wilms tumor 1 [WT1]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
TW105129257A 2015-09-10 2016-09-09 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法 TWI759270B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562216525P 2015-09-10 2015-09-10
US62/216,525 2015-09-10
US201562220641P 2015-09-18 2015-09-18
US62/220,641 2015-09-18

Publications (2)

Publication Number Publication Date
TW201714619A TW201714619A (zh) 2017-05-01
TWI759270B true TWI759270B (zh) 2022-04-01

Family

ID=57068181

Family Applications (1)

Application Number Title Priority Date Filing Date
TW105129257A TWI759270B (zh) 2015-09-10 2016-09-09 藉由t細胞療法治療多發性骨髓瘤及漿細胞白血病之方法

Country Status (14)

Country Link
US (1) US20190381098A1 (OSRAM)
EP (1) EP3347028A1 (OSRAM)
JP (1) JP6947720B2 (OSRAM)
KR (1) KR20180048992A (OSRAM)
CN (1) CN108348552A (OSRAM)
AU (1) AU2016320877A1 (OSRAM)
CA (1) CA2997757A1 (OSRAM)
HK (1) HK1257882A1 (OSRAM)
IL (1) IL257929B2 (OSRAM)
MX (1) MX395106B (OSRAM)
RU (1) RU2743381C2 (OSRAM)
TW (1) TWI759270B (OSRAM)
WO (1) WO2017044678A1 (OSRAM)
ZA (1) ZA201801656B (OSRAM)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018217203A1 (en) 2017-05-25 2018-11-29 Oreilly Richard John Use of the il-15/il-15ra complex in the generation of antigen-specific t cells for adoptive immunotherapy
AU2018355145A1 (en) 2017-10-23 2020-04-30 Atara Biotherapeutics, Inc. Methods of managing tumor flare in adoptive immunotherapy
EP3765602A1 (en) 2018-03-14 2021-01-20 Memorial Sloan Kettering Cancer Center Methods of selecting t cell line for adoptive cellular therapy
CN111643525A (zh) * 2020-06-16 2020-09-11 济宁医学院 引发免疫排斥反应在肿瘤治疗中的应用及其方法
CN113881632B (zh) * 2021-09-29 2023-09-29 四川省医学科学院·四川省人民医院 一种提高dc细胞活性的细胞培养基及培养方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200606176A (en) * 1998-09-30 2006-02-16 Corixa Corp Compositions and methods for wt1 specific immunotherapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1038929B (zh) * 1998-07-31 2005-05-06 株式会社国际癌症免疫研究所 基於癌抑制基因wt1的产物的癌抗原
US20080070835A1 (en) * 2003-11-05 2008-03-20 International Institute Of Cancer Immunology, Inc Hla-Dr-Binding Antigen Peptide Derived From Wt1
FR2931163B1 (fr) * 2008-05-16 2013-01-18 Ets Francais Du Sang Lignee de cellules dendritiques plasmacytoides utilisee en therapie cellulaire active ou adoptive
RU2506311C2 (ru) * 2008-10-30 2014-02-10 Йеда Рисёрч Энд Девелопмент Ко. Лтд. Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний
CA2861206C (en) * 2012-01-13 2021-07-06 Richard J. O'reilly Immunogenic wt-1 peptides and methods of use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200606176A (en) * 1998-09-30 2006-02-16 Corixa Corp Compositions and methods for wt1 specific immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
;2015年6月3日，Bone Marrow Transplantation (2015) 50, S43–S50 *
2007年12月01日，International Journal of HEMATOLOGY *
2015年6月3日，Bone Marrow Transplantation (2015) 50, S43–S50

Also Published As

Publication number Publication date
US20190381098A1 (en) 2019-12-19
MX2018002816A (es) 2018-06-08
IL257929B2 (en) 2024-06-01
EP3347028A1 (en) 2018-07-18
MX395106B (es) 2025-03-21
CN108348552A (zh) 2018-07-31
IL257929B1 (en) 2024-02-01
AU2016320877A1 (en) 2018-04-19
RU2018112526A (ru) 2019-10-10
JP6947720B2 (ja) 2021-10-13
TW201714619A (zh) 2017-05-01
IL257929A (en) 2018-05-31
JP2018530534A (ja) 2018-10-18
RU2018112526A3 (OSRAM) 2020-01-31
CA2997757A1 (en) 2017-03-16
RU2743381C2 (ru) 2021-02-17
HK1257882A1 (zh) 2019-11-01
WO2017044678A1 (en) 2017-03-16
KR20180048992A (ko) 2018-05-10
ZA201801656B (en) 2022-12-21

Similar Documents

Publication Publication Date Title
US20230002730A1 (en) Improved targeted t-cell therapy
KR102509006B1 (ko) 세포 면역치료요법 전 세포독성 사전컨디셔닝의 대체
JP6995645B2 (ja) 免疫原性ｗｔ１ペプチド及びその使用方法
US20210213066A1 (en) Improved cell therapy compositions for hematopoietic stem cell transplant patients
EP3294304B1 (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy
RU2743381C2 (ru) Способы лечения множественной миеломы и плазмоклеточного лейкоза посредством т-клеточной терапии
CA3126066A1 (en) Ex vivo activated t-lymphocytic compositions and methods of using the same
Tanaka et al. Adoptive transfer of neoantigen-specific T-cell therapy is feasible in older patients with higher-risk myelodysplastic syndrome
US20160375060A1 (en) Methods of Treating Glioblastoma Multiforme by T Cell Therapy
JP7514365B2 (ja) 養子免疫療法における腫瘍フレアを管理する方法
US10722563B2 (en) Prostate-specific tumor antigens and uses thereof
HK40050731A (en) Improved targeted t-cell therapy
Burchert Immune targeting of chronic myeloid leukemia to improve treatment outcome
EA043393B1 (ru) Замена цитотоксического предварительного кондиционирования перед клеточной иммунотерапией
HK40008076A (en) Replacement of cytotoxic preconditioning before cellular immunotherapy
HK1244697B (en) Methods of treating epstein-barr virus-associated lymphoproliferative disorders by t cell therapy

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees